POINT Biopharma Global Inc

NASDAQ:PNT   3:59:50 PM EDT
7.88
-0.12 (-1.50%)
Products, Regulatory

Point Biopharma Initiates Randomization For Its Phase 3 SPLASH Study Evaluating PNT2002 for mCRPC

Published: 09/23/2021 12:27 GMT
POINT Biopharma Global Inc (PNT) - Point Biopharma Announces Initiation of Randomization for Its Phase 3 Splash Study Evaluating Pnt2002 for Mcrpc.
Point Biopharma Global Inc - Initiated Patient Enrollment in Canada With Additional Countries to Begin Enrolling in 4q21.
Point Biopharma Global Inc - 25 Patient Dosimetry and Safety Run-in Met All Pre-specified Safety and Efficacy Criteria.